Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.57 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.50 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | FAP | Q12884 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.47 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16099508 | 0.87 | DPP4 (0.57) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL17509126 | 0.78 | DPP4 (0.59) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL16102825 | 0.78 | DPP4 (0.54) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL16993649 | 0.75 | DPP4 (0.56) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL10025046 | 0.75 | DPP4 (0.59) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL10196665 | 0.75 | POLB (0.73) | — | |
| SCHEMBL16099875 | 0.74 | KDM4E (0.49) | PARP1 | |
| SCHEMBL22688314 | 0.74 | DPP4 (0.58) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL9990111 | 0.74 | DPP4 (0.53) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL11948486 | 0.73 | DPP4 (0.60) | DPP4DPP8DPP7DPP9ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160039825-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN MA INC. | 2016-02-11 | — | — | US | claimed |
| US-20160039825-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN MA INC. | 2016-02-11 | — | — | US | disclosed |
| EP-2970302-A1 | S1P AND/OR ATX MODULATING AGENTS | Biogen MA Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014152725-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039825-A1 | S1P AND/OR ATX MODULATING AGENTS | ENPP2, S1PR1, S1PR2 | DPP4 2824/4885DPP8 2201/4885DPP7 2171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.